Mucosis: Vaccines that mimic nature




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Mucosis: Vaccines that mimic nature
Released on: December 15, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Mucosis B.
  • Summary
  • Participants
  • Company
Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM®, an intranasal vaccine to prevent respiratory syncytial virus infection. Our vaccines are based on the patented and validated Mimopath® technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in our proof-of-concept animal and human studies of our FluGEM® vaccine candidate
Mr. Thomas Johnston is Chief Executive Officer. Mr. Johnston joined Mucosis in May 2011 from Novavax where as Vice President of Strategy he developed and executed a regional partnership strategy with deals in India, Mexico, and South Korea. Prior to Novavax, Mr. Johnston served as an executive-level strategic consultant in a number of industries including biotech, and held various senior-level positions with a number of world-class organizations such as Comcast, Microsoft, and Schlumberger. Mr. Johnston holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University.
Mucosis was founded in 2007 and is built on the proprietary Mimopath® vaccine technology platform. The technology counts its origin at the Department of Molecular Genetics at the University of Groningen and Biomade Technology Foundation, the Netherlands. The company successfully secured funding (including non-dilutive) to advance its proof-of-concept program, FluGEM®, into a Phase I human clinical study in 2011 and to further develop its proprietary mucosal vaccine technology platform including its lead programs SynGEM and PneuGEM towards the clinic.